CRISPR/Cas9 screen reveals that targeting TRIM34 enhances ferroptosis sensitivity and augments immunotherapy efficacy in hepatocellular carcinoma.
Yao F, Zhou S, Zhang R, Chen Y, Huang W, Yu K, Yang N, Qian X, Tie X, Xu J, Zhang Y, Baheti T, Xu J, Dai X, Hao X, Zhang L, Wang X, Li Q.
Yao F, et al. Among authors: zhang l, zhang r, zhang y.
Cancer Lett. 2024 Jul 1;593:216935. doi: 10.1016/j.canlet.2024.216935. Epub 2024 May 3.
Cancer Lett. 2024.
PMID: 38704136